Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract CT090: DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas

Jaume Capdevila, Timon Vandamme, Patricia Niccoli, Saori Mishima, Ken Kato, Yiyuan Ma, Ping Sun, Lijiang Geng, Ulrich M. Lauer

Cancer Res (2024) 84 (7_Supplement): CT090.

https://doi.org/10.1158/1538-7445.AM2024-CT090

Published: 05 April 2024

View article titled, Abstract CT090: DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas

Journal Articles

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Cancer Res (2023) 83 (8_Supplement): CT119.

https://doi.org/10.1158/1538-7445.AM2023-CT119

Published: 14 April 2023

View article titled, Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <em>FGFR3</em> alterations (trial in progress)

Journal Articles

Specific Elimination of CD133⁺ Tumor Cells with Targeted Oncolytic Measles Virus

Patricia Bach, Tobias Abel, Christopher Hoffmann, Zoltan Gal, Gundula Braun, Iris Voelker, Claudia R. Ball, Ian C.D. Johnston, Ulrich M. Lauer, Christel Herold-Mende, Michael D. Mühlebach, Hanno Glimm, Christian J. Buchholz

Cancer Res (2013) 73 (2): 865–874.

https://doi.org/10.1158/0008-5472.CAN-12-2221

Published: 16 January 2013

View article titled, Specific Elimination of CD133<sup>+</sup> Tumor Cells with Targeted Oncolytic Measles Virus

Includes: Supplementary data

Journal Articles

Liver Cancer Protease Activity Profiles Support Therapeutic Options with Matrix Metalloproteinase–Activatable Oncolytic Measles Virus

Michael D. Mühlebach, Thomas Schaser, Martina Zimmermann, Sorin Armeanu, Kay-Martin O. Hanschmann, Roberto Cattaneo, Michael Bitzer, Ulrich M. Lauer, Klaus Cichutek, Christian J. Buchholz

Cancer Res (2010) 70 (19): 7620–7629.

https://doi.org/10.1158/0008-5472.CAN-09-4650

Published: 29 September 2010

View article titled, Liver Cancer Protease Activity Profiles Support Therapeutic Options with Matrix Metalloproteinase–Activatable Oncolytic Measles Virus

Includes: Supplementary data

Journal Articles

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Sorin Armeanu, Michael Bitzer, Ulrich M. Lauer, Sascha Venturelli, Anita Pathil, Matthias Krusch, Stephan Kaiser, Jürgen Jobst, Irina Smirnow, Annika Wagner, Alexander Steinle, Helmut R. Salih

Cancer Res (2005) 65 (14): 6321–6329.

https://doi.org/10.1158/0008-5472.CAN-04-4252

Published: 15 July 2005

View article titled, Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Journal Articles

Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes

Sorin Armeanu, Ulrich M. Lauer, Irina Smirnow, Martin Schenk, Thomas S. Weiss, Michael Gregor, Michael Bitzer

Cancer Res (2003) 63 (10): 2369–2372.

Published: 15 May 2003

View article titled, Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes

NARROW

Abstract CT090: DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Specific Elimination of CD133⁺ Tumor Cells with Targeted Oncolytic Measles Virus

Liver Cancer Protease Activity Profiles Support Therapeutic Options with Matrix Metalloproteinase–Activatable Oncolytic Measles Virus

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes

Email alerts

AACR Journals

Abstract CT090: DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus

Liver Cancer Protease Activity Profiles Support Therapeutic Options with Matrix Metalloproteinase–Activatable Oncolytic Measles Virus

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Specific Elimination of CD133⁺ Tumor Cells with Targeted Oncolytic Measles Virus